- Question
- Does empagliflozin, added to standard care after acute myocardial infarction in patients at risk of heart failure, reduce hospitalization for heart failure or death from any cause?
- Design
- Randomized, double-blind, placebo-controlled, multicenter, event-driven trial with 1:1 allocation and 6522 patients. Median follow-up was 17.9 months.
- Population
- Patients hospitalized for acute myocardial infarction and at risk of developing heart failure, enrolled within 14 days of admission.
- Intervention
- Empagliflozin 10 mg daily on top of standard care.
- Control
- Placebo on top of standard care.
- Primary outcome
- Composite of first hospitalization for heart failure or death from any cause, analyzed as time to first event.
- Results
- The primary endpoint occurred in 267 patients (8.2%) with empagliflozin and 298 (9.1%) with placebo (HR 0.90; 95% CI 0.76 to 1.06; P = 0.21). First hospitalization for heart failure occurred in 118 patients (3.6%) vs. 153 (4.7%) (HR 0.77; 95% CI 0.60 to 0.98), and death from any cause in 169 (5.2%) vs. 178 (5.5%) (HR 0.96; 95% CI 0.78 to 1.19).
- Safety
- Adverse events were consistent with the known safety profile of empagliflozin and were similar between the two groups.
- Conclusion
- In patients at increased risk of heart failure after acute myocardial infarction, empagliflozin did not significantly lower the risk of the composite of first hospitalization for heart failure or death from any cause compared with placebo.
- Why it matters
- It showed that the benefit of SGLT2 inhibitors seen in other cardiovascular settings did not translate into a significant reduction of the primary endpoint after acute myocardial infarction, although the lower rate of heart failure hospitalization provided a signal of interest for further research.
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 14, 2026